COR	LOE	RECOMMENDATIONS
1	B-NR	1. Patients with AF should be evaluated for their annual risk of thromboembolic events using a validated clinical risk score, such as CHA2DS2-VASc.1-4
1	B-NR	2. Patients with AF should be evaluated for factors that specifically indicate a higher risk of bleeding, such as previous bleeding and use of drugs that increase bleeding risk, in order to identify possible interventions to prevent bleeding on anticoagulation.5-7
2a	C-LD	3. Patients with AF at intermediate annual risk of thromboembolic events by risk scores (eg, equivalent to CHA2DS2-VASc score of 1 in men or 2 in women), who remain uncertain about the benefit of anticoagulation, can benefit from consideration of factors that might modify their risk of stroke to help inform the decision.*
3: No Benefit	B-NR	4. In patients who are deemed at high risk for stroke, bleeding risk scores should not be used in isolation to determine eligibility for oral anticoagulation but instead to identify and modify bleeding risk factors and to inform medical decision-making.8-10

^*Factors may include AF burden or other features in Table 3.